Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1643 1646
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18771839 | Combination Therapies with Anti-CD38 Antibodies | Non-Final OA | Janssen Biotech, Inc. |
| 17691050 | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses | Final Rejection | Janssen Biotech, Inc. |
| 18596320 | METHODS OF INDUCING CARDIAC CELL PROLIFERATION AND INDUCING HEART REGENERATION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18579425 | HUMAN IPSC-DERIVED MACROPHAGE | Non-Final OA | The Regents of the University of California |
| 18571833 | ANTIBODIES SPECIFIC TO NELL2 AND METHODS OF USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17704746 | METHODS AND COMPOSITIONS COMPRISING A CD93/IGFBP7 BLOCKING AGENT FOR TREATING CANCER | Final Rejection | The Regents of the University of Colorado, a body corporate |
| 17782338 | A T cell-based immunotherapy for central nervous system viral infections and tumors | Final Rejection | YALE UNIVERSITY |
| 17596118 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH COLLAGEN BINDING DRUG CARRIERS | Non-Final OA | The University of Chicago |
| 18668810 | COMBINATION THERAPY OF ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES AND TYRP1-SPECIFIC ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18037071 | FAB HIGH MANNOSE GLYCOFORMS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18253665 | FUSION PROTEINS COMPRISING AN E2 UBIQUITIN OR UBIQUITIN-LIKE CONJUGATING DOMAIN AND A TARGETING DOMAIN FOR SPECIFIC PROTEIN DEGRADATION | Non-Final OA | MEDIMMUNE LIMITED |
| 17759728 | MEANS AND METHOD FOR MODULATING IMMUNE CELL ENGAGING EFFECTS | Final Rejection | Merus N.V. |
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | Final Rejection | Merus N.V. |
| 17904890 | EX VIVO GAMMA DELTA T CELL POPULATIONS | Non-Final OA | GAMMADELTA THERAPEUTICS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy